Pegsunercept

From Self-sufficiency
Jump to: navigation, search
Pegsunercept
Clinical data
Routes of
administration
subcutaneous injection
Legal status
Legal status
  • investigational
Pharmacokinetic data
Bioavailability N/A
Identifiers
CAS Number 330988-75-5
ATC code none
Chemical data
Formula C502H758N154O165S16
Molar mass 12,103 g/mol (protein part)[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Jump up ClinicalTrials.gov NCT00037700 Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
  2. Jump up ClinicalTrials.gov NCT00111423 Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
  3. Jump up to: 3.0 3.1 Furst, DE; Fleischmann, R; Kopp, E; Schiff, M; Edwards C, 3rd; Solinger, A; Macri, M; 990136 Study, Group (2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of rheumatology. 32 (12): 2303–10. PMID 16331754.  edit